WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201613

CAS#: 807640-87-5 (free base)

Description: JNJ-26483327, also known as BGB102, is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3).

Chemical Structure

CAS# 807640-87-5 (free base)

Theoretical Analysis

MedKoo Cat#: 201613
Name: JNJ-26483327
CAS#: 807640-87-5 (free base)
Chemical Formula: C22H25BrN4O2
Exact Mass: 456.11609
Molecular Weight: 457.3635
Elemental Analysis: C, 57.77; H, 5.51; Br, 17.47; N, 12.25; O, 7.00

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 807640-87-5 (free base)   1021686-80-5 (2HBr salt)    

Synonym: JNJ26483327; JNJ 26483327; JNJ-26483327; BGB102; BGB-102; BGB 102.

IUPAC/Chemical Name: 35-bromo-17-methoxy-5-methyl-11-oxa-2,5-diaza-1(4,6)-quinazolina-3(1,2)-benzenacycloundecaphane


InChi Code: InChI=1S/C22H25BrN4O2/c1-27-8-4-3-5-9-29-21-11-17-19(12-20(21)28-2)24-14-25-22(17)26-18-10-16(23)7-6-15(18)13-27/h6-7,10-12,14H,3-5,8-9,13H2,1-2H3,(H,24,25,26)


Appearance: white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 457.3635 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Konings IR, de Jonge MJ, Burger H, van der Gaast A, van Beijsterveldt LE,
Winkler H, Verweij J, Yuan Z, Hellemans P, Eskens FA. Phase I and pharmacological
study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients
with advanced solid tumours. Br J Cancer. 2010 Sep 28;103(7):987-92. doi:
10.1038/sj.bjc.6605867. Epub 2010 Sep 7. PubMed PMID: 20823884; PubMed Central
PMCID: PMC2965873.

2: Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. HER2
phosphorylation is maintained by a PKB negative feedback loop in response to
anti-HER2 herceptin in breast cancer. PLoS Biol. 2010 Dec 21;8(12):e1000563. doi:
10.1371/journal.pbio.1000563. Erratum in: PLoS Biol. 2016 Mar;14(3):e1002414.
PubMed PMID: 21203579; PubMed Central PMCID: PMC3006345.

3: Danhier F, Ucakar B, Vanderhaegen ML, Brewster ME, Arien T, Préat V.
Nanosuspension for the delivery of a poorly soluble anti-cancer kinase inhibitor.
Eur J Pharm Biopharm. 2014 Sep;88(1):252-60. doi: 10.1016/j.ejpb.2014.05.014.
Epub 2014 May 21. PubMed PMID: 24859391.

Additional Information